

⑪ Publication number:

0 058 481
B1

⑫

EUROPEAN PATENT SPECIFICATION

⑬ Date of publication of patent specification: **01.10.86**

⑭ Application number: **82300416.3**

⑮ Date of filing: **27.01.82**

⑯ Int. Cl.⁴: **A 61 K 37/02, C 08 G 63/08 //**
C07K7/06, C07K7/10,
C07K15/06, A61K31/765,
A61K9/22

⑰ Continuous release pharmaceutical compositions.

⑱ Priority: **16.02.81 GB 8104734**

⑲ Date of publication of application:
25.08.82 Bulletin 82/34

⑳ Publication of the grant of the patent:
01.10.86 Bulletin 86/40

㉑ Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

㉒ References cited:
EP-A-0 025 698
GB-A-1 351 409
GB-A-2 008 135
US-A-3 773 919
US-A-3 887 699
US-A-4 011 312

Chemical Abstracts vol. 88, no. 12, March 1978
Columbus, Ohio, USA T.M.S. CHANG
"Biodegradable semipermeable microcapsules
containing enzymes, hormones, vaccines, and
other biologicals" page 79044, column 2,
abstract no. 79041n

The file contains technical information
submitted after the application was filed and
not included in this specification

㉓ Proprietor: **IMPERIAL CHEMICAL INDUSTRIES**
PLC
Imperial Chemical House Millbank
London SW1P 3JF (GB)

㉔ Inventor: **Hutchinson, Francis Gowland**
29 Woodland Drive
Lymm Cheshire WA13 0BL (GB)

㉕ Representative: **Atkinson, John David et al**
Imperial Chemical Industries PLC Legal
Department: Patents PO Box 6 Bessemer Road
Welwyn Garden City Hertfordshire, AL7 1HD
(GB)

㉖ References cited:
Chemical Abstracts vol. 91, no. 2, 1979
Columbus, Ohio, USA D. WISE et al. "Results
on biodegradable cylindrical subdermal
implants for fertility control" page 275, column
2, abstract no. 9442g
Polymer, Volume 20, pages 1459-1464. 1979

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

Courier Press, Leamington Spa, England.

BEST AVAILABLE COPY

EP 0 058 481 B1

Description

This invention relates to pharmaceutical compositions of pharmacologically-active acid-stable polypeptides, which provide continuous release of the polypeptide over an extended period when the composition is placed in an aqueous, physiological-type environment.

It has long been appreciated that the continuous release of certain drugs over an extended period following a single administration could have significant practical advantages in clinical practice, and compositions have already been developed to provide extended release of a number of clinically useful drugs, after oral dosing (see, for example, Remington's Pharmaceutical Sciences, published by Mack Publishing Company, Easton, Pennsylvania, U.S.A., 15th Edition, 1975, pages 1618—1631), after parenteral administration (*ibidem*, pages 1631—1643), and after topical administration (see, for example, United Kingdom Patent Number 1,351,409). A suitable method of parenteral administration is the sub-dermal injection or implantation of a solid body, for example a pellet or a film, containing the drug, and a variety of such implantable devices has been described. In particular, it is known that, for many drugs, suitable implantable devices for providing extended drug release may be obtained by encapsulating the drug in a biodegradable polymer, or by dispersing the drug in a matrix of such a polymer, so that the drug is released as the degradation of the polymer matrix proceeds.

Suitable biodegradable polymers for use in sustained release formulations are well known, and include polyesters, which gradually become degraded by hydrolysis when placed in an aqueous, physiological-type environment. Particular polyesters which have been used are those derived from hydroxycarboxylic acids, and much prior art has been directed to polymers derived from α -hydroxycarboxylic acids, especially lactic acid in both its racemic and optically active forms, and glycolic acid, and copolymers thereof—see, for example, United States Patents Numbers 3,773,919 and 3,887,699; Jackanicz *et al.*, Contraception, 1973, 8, 227—234; Anderson *et al.*, *ibidem*, 1976, 11, 375—384; Wise *et al.*, Life Sciences, 1976, 19, 867—874; Woodland *et al.*, Journal of Medicinal Chemistry, 1973, 16, 897—901; Yolles *et al.*, Bulletin of the Parenteral Drug Association, 1976, 30, 306—312; Wise *et al.*, Journal of Pharmacy and Pharmacology, 1978, 30, 686—689 and 1979, 31, 201—204.

In this specification, the term "polylactide" is used in a generic sense to include polymers of lactic acid alone, copolymers of lactic acid and glycolic acid, mixtures of such polymers, mixtures of such copolymers, and mixtures of such polymers and copolymers, the lactic acid being either in racemic or in optically active form. Also, the term "acid-stable" is to be understood as meaning that the polypeptide is not significantly hydrolysed under the conditions encountered within the claimed formulations during the period of use envisaged, that is, at pH 2 at mammalian body temperature, say up to 40°C, for up to six months.

United Kingdom Patent Specification Number 1,325,209 (equivalent to United States Patent Specification Number 3,773,919) and United States Patent Specification Number 3,887,699 is the only prior art known to us which makes any reference to extended or sustained release of polypeptides, the latter mentioning insulin only, but it contains no specific example of any such formulation, and the reference to polypeptides is apparently entirely speculative, appearing, as it does, only in an extensive listing of very many different classes of drugs which can allegedly be incorporated into formulations of the kind described therein. In fact, essentially all of the other drug types referred to in that specification, apart from polypeptides, are relatively hydrophobic in character and of relatively low molecular weight, and the disclosure of that specification displays no recognition of the difficulties which we have encountered when seeking to obtain satisfactory sustained release formulations of polypeptides, many of which are relatively hydrophilic, and of relatively high molecular weight.

It is to be appreciated that "sustained" or "extended" release of a drug may be either continuous or discontinuous. We have now discovered, in fact, that in many cases when the teaching of the prior art, and in particular the teaching of United Kingdom Specification No. 1,325,209, is applied to the manufacture of a formulation of an acid-stable polypeptide, the release of the polypeptide from the formulation, although occurring over an extended period of time, may also be discontinuous. For example, the release of a polypeptide from a polylactide polymer as described in the said Specification is often preceded by a significant induction period, during which no polypeptide is released, or is biphasic, and comprises an initial period during which some polypeptide is released, a second period during which little or no polypeptide is released, and a third period during which most of the remainder of the polypeptide is released. By contrast, it is an object of the present invention to provide compositions of acid-stable polypeptides from which, apart possibly from a relatively short initial induction period, the polypeptide is released continuously, with no periods during which little or no polypeptide is released. The words "continuous release" are used in this specification solely to describe a release profile which is essentially monophasic, although it may have a point of inflection, but certainly has no "plateau" phase.

In Journal of Bioengineering, 1, 25—29 (1976) (Chemical Abstracts, 88, 7904/n, 1978), two formulations of insulin are disclosed which show an essentially monophasic release profile, but substantially all the insulin is released within about 48 hours.

Thus, according to the present invention, there is provided a pharmaceutical composition comprising a polylactide, which is a polymer of lactic acid alone, a copolymer of lactic and glycolic acids, a mixture of such polymers, a mixture of such copolymers or a mixture of such polymers and copolymers, and an acid-stable polypeptide, which is not significantly hydrolysed under the conditions encountered within the

composition during the period of use envisaged, which composition, when placed in an aqueous physiological-type environment, releases the polypeptide into the aqueous physiological-type environment in continuous manner, giving a release profile which is essentially monophasic, although it may have a point of inflection, but certainly has no "plateau" phase, over a period of at least one week; but
 5 excluding a composition in microcapsule form comprising at least one polypeptide which is a naturally occurring luteinising hormone releasing hormone (LH—RH), a synthetically prepared material of the same type or synthetically prepared analogues of naturally occurring LH—RH which act in some manner on the anterior pituitary gland to affect the release of luteinising hormone (LH) and follicle stimulating hormone (FSH).

10 This invention is applicable to acid-stable polypeptides quite generally, without any limitation as to structure or molecular weight, but is most useful for polypeptides which are relatively hydrophilic, and the following list, which is not intended to be exhaustive, is indicative of polypeptides, which may be employed in the formulation of this invention:— oxytocin, vasopressin, adrenocorticotrophic hormone (ACTH), epidermal growth factor (EGF), prolactin, luteinizing hormone releasing hormone (LH—RH),
 15 insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, renin, bradykinin, tyrocidin, gramicidines, and synthetic analogues and modifications and pharmacologically-active fragments thereof.

We have found, however, that polypeptides which are not stable under acid conditions, are unsuitable for use in the compositions of this invention, as they become degraded in the acid environment produced
 20 in the polymer matrix when the polylactide starts to degrade by hydrolysis, thus producing carboxylic acid end groups.

By "an aqueous physiological-type environment" we mean the body, particularly the musculature or the circulatory system, of a warm-blooded animal, although in laboratory investigations such an environment may be mimicked by aqueous liquids, optionally buffered to a physiological pH, at a
 25 temperature of between 35 and 40°C.

The continuous release composition of the invention may be placed in the body of an animal which it is desired to treat with a polypeptide by, for example, intramuscular or subcutaneous injection, or by sub-dermal surgical implantation, in conventional clinical or veterinary manner.

We have discovered that a pharmaceutical composition according to the invention may be designed to
 30 provide continuous release of the polypeptide by the appropriate choice or control of various parameters, for example by varying the polylactide composition, particularly the proportion of lactic acid to glycolic acid in copolymers; by controlling the molecular weight of the polylactide, both the weight-average molecular weight, and the molecular weight range of polydispersity, measured by the ratio of the weight-average molecular weight, (M_w), to the number-average molecular weight (M_n), i.e.

35

$$\frac{M_w}{M_n};$$

40 by choice of the proportion of polypeptide to polylactide; or by choice of the geometry of a solid formulation for implantation, or of the particle size in a formulation for injection. The release characteristics of such compositions are also controlled to some extent by the nature of the polypeptide itself. In particular, there is less freedom of choice in defining the parameters mentioned above when designing a composition of the invention for a polypeptide of high molecular weight, (say, greater than 6000), than
 45 there is when designing a composition for a polypeptide of lower molecular weight, (say, less than 6000).

We have further discovered that the release of a polypeptide from a composition comprising a polylactide and a polypeptide proceeds by two distinct and independent mechanisms, namely first a diffusion-dependent release of polypeptide out of the polylactide-polypeptide matrix comprising leaching
 50 from the surface, and, for low molecular weight polypeptides, some partition-dependent diffusion of polypeptide per se; and subsequently, as the polylactide becomes degraded, diffusion of aqueous polypeptide solution out of the composition through aqueous channels.

In general, the compatibility of polypeptides in polylactide polymers is limited, except in the case of low molecular weight (up to, say, 6000 molecular weight) polypeptides which are capable of having some specific interaction with the polylactide, for example a low molecular weight polypeptide which is basic,
 55 and which therefore interacts with the terminal carboxylic acid groups in the polylactide. Because of this limited compatibility of polypeptide in polylactide, a polypeptide/polylactide formulation, when placed in an aqueous environment, releases very little polypeptide by diffusion through the polymer matrix. While this is broadly true for all combinations of polypeptide and polylactide, matrix diffusion is at a minimum for high molecular weight polypeptides in high molecular weight polylactides. Even when some matrix
 60 diffusion resulting in polypeptide release occurs initially on placing the composition in an aqueous environment, by release, from or very near the surface, this soon ceases because the diffusion of polypeptide into polylactide is insufficient to result in continuous transport of polypeptide from inside the composition to its surface.

When a polypeptide/polylactide composition is placed in an aqueous environment, water diffuses into
 65 the matrix, and is partitioned between polypeptide and polylactide to form domains of aqueous

polypeptide solution. This aqueous polypeptide, obtained when absorbed water is partitioned between polypeptide and polylactide, is incompatible with, and insoluble in, polylactides, particularly those of high molecular weight, so that absorption of water by the composition still further reduces initially any likelihood of matrix diffusion of polypeptide out of the composition. If the aqueous domains of polypeptide so formed are discrete and isolated, then the compositions are incapable of releasing polypeptide. However, the possibility of the aqueous polypeptide domains having some continuity increases with increasing concentration of polypeptide in the composition, and with increasing absorption of water, and when the continuity of aqueous polypeptide domains reaches a sufficient level to communicate with the exterior surface of the composition, polypeptide starts to be released from the formulation by diffusion, not through the polylactide matrix, but through aqueous polypeptide channels. Even when some aqueous polypeptide domains near the surface have extended so as to reach the exterior of the composition, that aqueous polypeptide which exists in still isolated domains is not released, and is only released when a secondary hydrophilic path for diffusion becomes available. For high molecular weight polylactides, this secondary hydrophilic diffusion path arises when the polylactide has undergone sufficient degradation for the rate of absorption of water to increase significantly. When this occurs, aqueous pores or channels are generated in the polylactide matrix, which allow a continuous and significant release of polypeptide, as aqueous solution, from previously discrete and isolated domains.

As indicated above, we have discovered that, when sustained release compositions of the prior art, and particularly those described in United Kingdom Patent Specification Number 1,325,209, are used for the release of polypeptides, the initial matrix diffusion phase of polypeptide release, and the secondary release of polypeptide consequent upon degradation of the polylactide, are separated in time with the result that the release of polypeptide is not continuous, but is biphasic and discontinuous, comprising a small first release of polypeptide, a dead phase during which essentially no polypeptide is released, and subsequent second release phase, during which substantially all of the remaining polypeptide is released. We have now discovered that, by appropriate choice of the parameters of the composition, the matrix diffusion phase of release, and subsequent degradation induced phase of release, can be made to overlap in time.

Thus, according to a further feature of the invention there is provided a pharmaceutical composition comprising a polylactide which is a polymer of lactic acid alone, a copolymer of lactic and glycolic acids, a mixture of such polymers, a mixture of such copolymers or a mixture of such polymers and copolymers, and an acid-stable polypeptide, which is not significantly hydrolysed under the conditions encountered within the composition during the period of use envisaged, which composition, when placed in an aqueous physiological-type environment, exhibits two successive phases of release of the polypeptide, the first phase being released by matrix diffusion and the second phase being released consequent upon degradation of the polylactide, characterised in that the diffusion phase and the degradation-induced phase overlap in time, and release of polypeptide occurs over a period of at least one week; but excluding a composition in microcapsule form comprising at least one polypeptide which is a naturally occurring luteinising hormone releasing hormone (LH—RH), a synthetically prepared material of the same type or synthetically prepared analogues of naturally occurring LH—RH which act in some manner on the anterior pituitary gland to affect the release of luteinising hormone (LH) and follicle stimulating hormone (FSH).

The two phases can be made to overlap by either extending the initial diffusion phase, or making the degradation-induced phase commence earlier, or both.

The initial matrix release phase is difficult to extend, but is sensitive to the concentration of the polypeptide in the matrix, and to a limited extent, to the nature of the polypeptide, especially its hydrophilicity.

The degradation-induced release phase can be made to start sooner by appropriate choice of polylactide composition (more glycolide-rich polymer molecules, which degrade more quickly than lactide-rich molecules), M_w (molecules of low molecular weight degrade more quickly to a level at which aqueous channels appear in the matrix), and polypeptide concentration (a higher polypeptide concentration allows more rapid absorption of water, and consequently more rapid generation of continuous aqueous channels which facilitate polypeptide release).

However, as well as requiring the degradation induced release phase to start earlier, it is also necessary to control the rate of polypeptide release during this phase, and to ensure that the total duration of this phase is sufficient for its intended clinical or veterinary purpose. One method of extending the duration of the degradation-induced release phase, is to use polylactides which contain lactide-rich molecules, which degrade more slowly than glycolide-rich molecules, or alternatively, polylactides containing molecules of high molecular weight, which take longer to degrade to a level at which aqueous channels are formed, can be used.

It is apparent, therefore, that since glycolide-rich polymer molecules, and/or molecules of low molecular weight, are preferred if the degradation phase is to start quickly, and lactide-rich molecules, and/or molecules of high molecular weight are preferred if the degradation-induced release phase is to last for a sufficient period of time, preferred polylactides are those with a high degree of heterogeneity, in respect of glycolide-rich and lactide-rich molecules, or of high polydispersity.

Alternatively, the same characteristics can be obtained by blending two or more different polylactides, which differ in lactide/glycolide content, and/or in M_w . In addition, the blending of a minor proportion of polylactide of high M_w with a polylactide of low M_w , confers desirable physical properties upon

compositions according to this invention produced therefrom, making them easier to fabricate and process.

We have further discovered that the profile of polypeptide release from both prior art polylactides and novel polylactides is almost exactly paralleled by the profile of water absorption. That is to say, when polypeptide release is discontinuous, water absorption is also discontinuous in essentially the same manner, and conversely, when polypeptide release is continuous, so is water absorption. Furthermore, variation of the parameters referred to above for controlling the polypeptide release characteristics of the composition have been found to affect water absorption by the composition in an exactly parallel manner.

Thus, according to a further feature of the invention there is provided a pharmaceutical composition comprising a polylactide which is a polymer of lactic acid alone, a copolymer of lactic and glycolic acids, a mixture of such polymers, a mixture of such copolymers or a mixture of such polymers and copolymers, and an acid-stable polypeptide, which is not significantly hydrolysed under the conditions encountered within the composition during the period of use envisaged, which composition, when placed in an aqueous physiological-type environment, absorbs water in a continuous manner, giving a water absorption profile which is essentially monophasic, although it may have a point of inflection, but certainly no "plateau" phase, until the polylactide has been degraded and essentially all of the polypeptide has been released into the aqueous physiological-type environment over a period of one week; but excluding a composition in microcapsule form comprising at least one polypeptide which is a naturally occurring luteinising hormone releasing hormone (LH—RH), a synthetically prepared material of the same type or synthetically prepared analogues of naturally occurring LH—RH which act in some manner on the anterior pituitary gland to affect the release of luteinising hormone (LH) and follicle stimulating hormone (FSH).

The effect of the various parameters, referred to above, on the polypeptide release and/or water absorption characteristics of compositions of the invention is illustrated by the following experiments:—

A. Molecular weight of the polylactide component

A.1. Low molecular weight polypeptide.


A.1.1. Formulations were manufactured comprising 20% w/w of the gastric peptide fragment tetragastrin hydrochloride, Trp-Met-Asp-Phe-NH₂ · HCl, molecular weight=633, in a polylactide comprising equimolar proportions of D,L-lactide and glycolide units, in the form of a film 0.2 mm thick. The films were placed individually in water at 37°C, which was changed daily, and the ultraviolet absorption at 277 nm was measured to assay the tetragastrin released by the formulation that day.

With a prior art type of polylactide of M_w approximately 240,000 (intrinsic viscosity=1.36), there was an initial release of tetragastrin, then a "dead period" from about day 5 to day 21 during which little was released, followed by the main release from day 24 onward.

With a novel polylactide of M_w approximately 15,000 (intrinsic viscosity=0.25), the release pattern was similar, but the dead period lasted only from day 4 or 5 to day 8 or 9.

With a novel polylactide of low M_w (inherent viscosity of a 1 g/100 ml solution in chloroform=0.11), there was no dead period, and tetragastrin was released continuously from time zero (T_0).

A.1.2. Similar formulations were manufactured using 10% by weight of the synthetic luliberin analogue ICI.118,630,



molecular weight=1269, in place of tetragastrin.

With a prior art polylactide of M_w ~240,000 (intrinsic viscosity=1.36), the release of the polypeptide was biphasic, with a dead period of about 15 days.

With a novel polylactide of M_w ~15,000 (intrinsic viscosity=0.25), there was a short induction period, followed by continuous release.

With a novel polylactide of low M_w (inherent viscosity of a 1 g/100 ml solution in chloroform=0.11), there was continuous release from T_0 .

A.2. Medium molecular weight polypeptide.

Formulations were manufactured comprising 0.1% by weight of mouse epidermal growth factor (EGF), molecular weight=6041, in polylactides comprising equimolar proportions of D,L-lactic acid and glycolic acid units, and of different M_w , and placed in pH 7.4 buffer. Release of EGF was monitored by radio-immunoassay.

With a prior art polylactide of M_w ~200,000 (intrinsic viscosity=1.08), there was no initial release, and no significant release of polypeptide until between 13 and 20 days after T_0 , after which release was continuous.

With a polylactide of M_w ~80,000 (intrinsic viscosity=0.58), there was also no initial release, and significant release did not occur until between 6 and 10 days after T_0 , after which release was continuous.

With a novel polylactide of low M_w (inherent viscosity of a 1 g/100 ml solution in chloroform=0.11), there was continuous release from T_0 .

A.3. High molecular weight polypeptide

A formulation was manufactured comprising 20% w/w of bovine prolactin, molecular weight ~22,000, in a novel polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units, and of low M_w (inherent viscosity of a 1 g/100 ml solution in chloroform=0.11). As expected from previous experiments A.1.1., A.1.2. and A.2., this formulation also released polypeptide continuously from T_0 when tested *in vivo* in rats, and circulating bovine prolactin assayed by radio-immunoassay.

Experiments A.1. to A.3. thus demonstrate that reducing the molecular weight, M_w , or viscosity of the polylactide used in the manufacture of a composition reduces the biphasicity of polypeptide release, for polypeptides of low or medium molecular weight, or the initial delay in release of polypeptides of medium or high molecular weight, and achieves a continuous release of the polypeptide from T_0 .

B. Ratio of lactide/glycolide in the polylactide

Compositions were manufactured in the form of implants containing 100 µg (3% w/w) of the luliberin analogue ICI. 118,630 in polylactides of $M_w \sim 300,000$ but of different lactide/glycolide ratios. All of these formulations when tested *in vivo* in adult female rats exhibiting normal oestrous behaviour, gave biphasic release of the polypeptide, comprising release for about 6 days post-treatment, followed by a dead period, during which there was no significant polypeptide release. The length of this dead period decreased with decreasing lactide/glycolide ratio (L/G), as follows:—

L/G	Dead period (days)
100/0	no release
75/25	51
67/33	34
50/50	15

This experiment thus indicates that a composition exhibiting a biphasic release of polypeptide can be improved in the direction of achieving continuous release by increasing the proportion of glycolide to lactide in the polylactide used, up to about 50% glycolide.

C. Ratio of polypeptide to polylactide

Compositions in the form of implants were manufactured using different concentrations of the synthetic luliberin analogue, ICI.118,630, in a prior art 50/50 lactide/glycolide polylactide of $M_w \sim 200,000$, and tested *in vivo* in rats as described above. At 5% and 10% w/w incorporation, the release of polypeptide was biphasic, but at 15% and 20% incorporation, the biphasicity disappeared.

This experiment thus demonstrates that a polylactide of high molecular weight, which gives biphasic release of polypeptide when the polypeptide is incorporated only at low levels, can be used to make satisfactory continuous release formulations if the proportion of polypeptide is increased sufficiently.

D. Molecular weight distribution

A solution of a polymer blend of wide molecular weight distribution (polydispersity) was obtained by mixing solutions of a 50/50 D,L-lactide/glycolide polylactide of low M_w , (reduced specific viscosity of a 1 g/100 ml solution chloroform=0.115), (3 parts by weight) and a 50/50 D,L-lactide/glycolide polylactide of $M_w = 200,000$, (intrinsic viscosity=1.08), (1 part by weight). Tetragastrin (1 part by weight) was added, and the mixture was cast to give a polylactide/tetragastrin composition containing 20% by weight of tetragastrin, and this was then moulded to give a slab 0.02 cm thick. The slab was placed in water at 37°C and the release of tetragastrin was found to be continuous from T_0 , and to continue for at least 44 days.

Polylactides of wide molecular weight distribution may be obtained either by mixing preformed polymers of different molecular weights, or by appropriate control of the polymerisation process in generally known manner, and such polylactides confer important advantages, for example the lower molecular weight polylactide species allow an essentially immediate release of some polypeptide, while the higher molecular weight polylactide species both extend the release period and slow down the overall rate of release of the polypeptide. In addition, the blending of low and high M_w fractions modifies the water absorption characteristics of the polylactide in a parallel manner.

E. Thickness of the implant

E.1. A solution of 10% by weight of tetragastrin in a polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units, and of $M_w \sim 15000$ was cast into films 0.02, 0.06 and 0.12 cm thick. All three films showed continuous release of tetragastrin from T_0 , and at 28 days, the three films had released respectively 85, 75 and 66% of their tetragastrin content.

E.2. The uptake of tritiated water from pH 7.4 buffer by slabs of polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units of $M_w \sim 200,000$, and intrinsic viscosity = 1.08 and of thickness 0.02, 0.06, 0.12 and 0.20 cm was measured by removing such slabs from the buffer solution successively after varying times of immersion, and measuring the tritium content by scintillation counting. After 5 weeks, the different thickness slabs had absorbed respectively 44, 20, 15 and 11% by weight of water.

These experiments show how the thickness of the implant can be used to control the absorption of water by, and thus the rate of release of polypeptide from, a composition of the invention, thicker implants releasing the polypeptide more slowly than thinner ones.

As indicated above the composition of the invention may be formulated as a solid composition for sub-dermal injection or implantation or as a liquid formulation for intramuscular or subcutaneous injection.

Suitable solid compositions for sub-dermal injection or implantation are, for example, rods, spheres, films or pellets, and cylindrical rods which can be injected through a hypodermic needle or trochar are preferred. Such compositions are manufactured by conventional techniques which are well known in the pharmaceutical art.

Preferred solid compositions of the invention, for polypeptides within different molecular weight ranges, are as shown in Table 1, and preferred compositions for specific polypeptides of particular interest are as shown in Table 2. Each entry in Tables 1 and 2 thus defines a further feature of this invention.

TABLE 1

No.	Polypeptide M.W.	Polylactide inherent viscosity*	<u>Glycolide</u> Lactide	% Poly-peptide	Preferred % poly-peptide
1.	<2000	>0.5	0.5—3	5—50	10—30
2.	<2000	0.2—0.5	0.2—3	5—50	
3.	<2000	<0.2	0—3	0.1—50	
4.	1500—10,000	0.4—0.8	0.5—3	10—50	20—50
5.	1500—10,000	0.15—0.4	0.2—3	5—30	10—30
6.	1500—10,000	<0.15	0—3	0.1—20	1—20
7.	8000—30,000	0.15—0.4	0—3	0.1—50	—
8.	8000—30,000	0.1—0.15	0.7—3	10—50	
9.	8000—30,000	<0.1	0—3	0.1—50	

* dl/g (1 g per 100 ml in chloroform or dioxan)

TABLE 2

No.	Polypeptide	Polylactide inherent viscosity*	Glycolide	% Poly-peptide
			Lactide	
10.	Tetragastrin	>0.5	1—3	5—50
11.	Tetragastrin	0.2—0.5	0.5—3	5—50
12.	Tetragastrin	<0.2	0—3	0.1—50
13.	ICI.118630	>0.5	0.8—3	5—50
14.	ICI.118630	0.2—0.5	0.2—3	5—50
15.	ICI.118630	<0.2	0—3	0.1—50
16.	EGF	0.4—0.8	0.5—3	10—50
17.	EGF	0.15—0.4	0—3	0.1—50
18.	Prolactin	<0.15	0—3	0.1—50

* dl/g (1 g per 100 ml in chloroform or dioxan).

Also as indicated above, the composition of the invention may also be formulated as a suspension for injection. Such suspensions may be manufactured by general techniques well known in the pharmaceutical art, for example by milling the polylactide/polypeptide mixture in an ultracentrifuge mill fitted with a suitable mesh screen, for example a 125 μ m (120) mesh, and suspending the milled, screened particles in a solvent for injection, for example propylene glycol, water optionally with a conventional viscosity increasing or suspending agent, oils or other known, suitable liquid vehicles for injection.

The continuous release of ICI.118630 from a suspension composition of the invention was demonstrated by comparing the dioestrous behaviour of normal mature female rats dosed subcutaneously with either a propylene glycol suspension of particles milled to 120-mesh size and containing 3% by weight of ICI.118630 in a polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units, and a $M_w \sim 240,000$, (intrinsic viscosity=1.36), or with a saline solution of 100, 200 or 300 μ g of ICI.118630 per animal. With the saline solutions, there was an immediate short period of dioestrus, but after 3 days post-dosing normal cyclicity was re-established. With the suspension composition of the invention, by contrast, the animals were substantially in dioestrus for about 40 days. Similar results were obtained with an injection formulation based on a mixture of 1% of ICI.118630 in a similar polylactide having an intrinsic viscosity of >0.5.

Thus, according to a further feature of the invention there is provided a suspension formulation for injection comprising from 1 to 50% by weight of a solid formulation, which itself comprises from 0.1 to 50% by weight of an acid-stable polypeptide which is not significantly hydrolysed under the conditions encountered within the composition during the period of use envisaged, and from 50 to 99.9% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0 to 3 and which is either soluble in benzene and has an inherent viscosity (1 g/100 ml solution in benzene) of less than 0.5 dl/g or is insoluble in benzene and has an inherent viscosity (1 g/100 ml solution in chloroform or dioxan) of less than 4 dl/g, which solid formulation has been reduced to fine particle size, together with from 50 to 99% by weight of a liquid carrier suitable for injection into mammals.

It is to be noted that, because of the reduced particle size of the polypeptide/polylactide in a suspension for injection, certain solid formulations, which are not suitable for implantation, are rendered useful when reduced to fine particle size and formulated as a suspension for injection. For example, the two particular suspension formulations referred to above both contain less ICI.118,630 than has been found acceptable for implantable formulations, as shown in Tables 1 and 2 above.

From the foregoing, it is clear that it is desirable to manufacture polylactides of a range of M_w , particularly of low to medium M_w in the range up to 60,000, and of high polydispersity

$$\frac{M_w}{M_n}$$

these being particularly valuable in the compositions of this invention. The prior art relating to polylactides

in general, and to copolymers containing lactic acid and glycolic acid units in particular, is largely silent as to the manufacture of such copolymers of low molecular weight, and as to methods of achieving high polydispersity in such copolymers. Indeed, it is inherent in the prior art disclosure of polylactides that they are generally of M_w greater than about 30,000—60,000 (an inherent viscosity of greater than 0.5) and of low polydispersity, due to their manufacture under anhydrous conditions and without any added chain-stoppers.

Certain polylactides within this range have, however, been disclosed. For example, United States Patent Number 4,011,312 discloses copolymers having molecular weights in the range 1200—1800, and Polymer, 20, 1459—1464 (1979), United States Patent Number 3,773,919, United Kingdom Patent Number 1,351,409 and Chemical Abstrats., 91, 9442 g (1979) discloses polymers having a molecular weight upward of about 35,000, corresponding to an inherent viscosity of greater than about 0.5.

We have realised that, because of the different reactivities under polymerisation conditions of the cyclic dimers of lactic acid and glycolic acid, copolymers of high heterogeneity in respect of polymer species may be obtained by ring opening polymerisation of a mixture of the two cyclic dimers in the presence of chain-stopping agents, to give polylactides having an inherent viscosity of less than 0.5. The cyclic dimer of glycolic acid is the more reactive under polymerisation conditions, and thus the first copolymer molecules formed in the polymerisation are glycolic acid-rich. Consequentially, the later copolymer molecules formed are necessarily lactic acid-rich, thus producing a copolymer of lactic acid and glycolic acid of the desired high heterogeneity.

In addition, we control the polymerisation to produce copolymers in the desired low M_w range by carrying out the ring opening copolymerisation of the mixed cyclic dimers in the presence of water, of lactic acid containing water, or of some other known chain growth regulator, in accordance with the general knowledge in the polymer art.

Suitable polymerisation catalysts are zinc oxide, zinc carbonate, basic zinc carbonate, diethylzinc, organotin compounds, for example stannous octanoate, tributylaluminium, titanium, magnesium or barium compounds, or litharge, and of these stannous octanoate is preferred.

The copolymerisation of the mixed cyclic dimers is otherwise carried out in conventional manner, known in the polymer art, as regards time and temperature.

Low molecular weight polylactides may also be obtained by copolymerisation of the hydroxy-acids themselves rather than the cyclic dimers. Although less heterogeneous polymers are obtained by this process, suitable matrices for continuous release of polypeptides may be obtained by mixing such polylactides of different compositions made by this method, or by mixing a polylactide made by this method with one or more polylactides made by ring opening polymerisation of the cyclic dimers.

Certain of the polymers described herein are novel and form a further feature of this invention. Thus according to a further feature of the invention there is provided a heterogeneous polymer containing from 25 to 100% molar of lactic acid units and from 0 to 75% molar of glycolic acid units, and which has an inherent viscosity (1 g/100 ml solution in chloroform or dioxan) equal to or greater than 0.09 and has an intrinsic viscosity equal to or less than 0.33. By a "heterogeneous polymer" we mean polymers with a high degree of heterogeneity, in respect of glycolide-rich and lactide-rich molecules, or of high polydispersity, or blends of two or more different polylactides which differ in lactide/glycolide content and/or M_w , as hereinbefore described.

Whether or not a particular copolymer is heterogeneous or not, in this sense, may be readily determined from inspection of the 25 MHz ^{13}C nuclear magnetic resonance spectrum of the copolymer in, for example, deuterated dimethyl sulphoxide. In a homogeneous copolymer, such as is obtained in the prior art copolymerisation of lactic acid and glycolic acid monomers, the resonance of the glycolic acid unit carbonyl carbon, at $\delta=166.0\text{—}166.2$ approximately, appears as two doublets, as a consequence of the four different, approximately equally probable molecular environments in which this carbon atom can exist, namely GGG, LGG, GGL and LGL (G=a glycolic acid unit, L=a lactic acid unit, and the asterisk indicates the glycolic acid unit under consideration). In a heterogeneous copolymer, on the other hand, such as is used in the present invention, the sequence LGL is unlikely to occur, so that one of the doublet signals in the spectrum of the homogeneous copolymer appears as a singlet. In fact, we find that in the spectrum of heterogeneous copolymers, this glycolic acid unit carbonyl carbon signal often appears as two singlets. Thus, a "heterogeneous copolymer" as herein defined is a copolymer for which the glycolic acid carbonyl carbon signal in the ^{13}C n.m.r. appears as other than a pair of doublets.

The heterogeneity or homogeneity of lactic acid/glycolic acid copolymers can also be demonstrated by an examination of their degradation. Thus, when a copolymer is placed in pH 7.4 buffer at 37°C, removed periodically, dried and sampled, and the ratio of lactic acid to glycolic acid units in the samples is determined by n.m.r., for a heterogeneous copolymer, the ratio L/G increases with time, as the glycolic acid sequences hydrolyse preferentially. For a homogeneous copolymer, on the other hand, the ratio of L/G remains essentially constant as degradation progresses.

The lactic acid content of the copolymer is preferably in the racemic (D,L) form, or in the optically active L form.

According to a further feature of the invention there is provided a process for the manufacture of a novel polymer or copolymer of lactic acid and glycolic acid as defined immediately above, which comprises the ring opening copolymerisation of the cyclic dimer of lactic acid and, optionally in the presence of the

cyclic dimer of glycolic acid, at elevated temperature in the presence of one of the above-mentioned polymerisation catalyst and in the presence of a chain stopping agent.

A suitable chain stopping agent is, for example, water, lactic acid, glycolic acid or other hydroxy acids, alcohols or carboxylic acids generally.

5" The invention is illustrated but not limited by the following Preparations and Examples:—

Preparation 1

Zinc oxide (16 g) was added to D,L-lactic acid (800 g) in a 2 l 3-necked round bottom flask-equipped with a stirrer, a thermometer, and a distillation head connected to a water condenser. The mixture was stirred
10 and heated to about 135°C, at which temperature water started to distil over. Heating was continued for 8 h, during which time the temperature rose to about 190°C. When distillation of water ceased, the pressure was reduced, and distillation was continued until solid began to collect in the condenser. At this stage the water condenser was replaced by an air condenser, and the residue was cooled and then distilled under high vacuum [2.66—10.64 mbar (2—8 mm of mercury)], the fraction (about 300 g) distilling between 130 and
15 160°C being collected, this being D,L-lactide (3,6 - dimethyl - 1,4 - dioxan - 2,5 - dione), the cyclic dimer of D,L-lactic acid.

The crude D,L-lactide was crystallised from ethyl acetate (approximately 600 ml) three times, and the recrystallised product was finally dried at 45°C under reduced pressure [2.66 mbar (2 mm of mercury)] for 24—48 hours, after which it had m.p. 124—125°C.

20 Preparation 2

Glycolide (1,4-dioxan-2,5-dione), the cyclic dimer of glycolic acid, was prepared by the method described in Preparative Methods in Polymer Chemistry by W. R. Sorenson and T. W. Campbell, second edition, published by Interscience (1968), page 363. The crude glycolide was purified by three successive
25 crystallisations from dry ethyl acetate, then dried at 45°C under reduced pressure [2.66—10.64 mbar (2—8 mm of mercury)] for 24—48 h, m.p. 82—84°C.

Examples 1 to 13

Polymers of D,L-lactide and glycolide were prepared as follows:—

30 Pure dry D,L-lactide (Preparation 1), pure dry glycolide (Preparation 2) totalling 42 g, commercial D,L-lactic acid containing about 12% by weight of water, and 1 ml of an 8% by weight solution of stannous octanoate in hexane, were placed in a pre-dried glass tube. The hexane was evaporated under reduced pressure, and the tube was heated at 160°C for 6 hours with constant agitation if possible. The tube was cooled in powdered solid carbon dioxide, and the polylactide was removed, broken into small pieces and
35 dissolved in chloroform (400ml). The chloroform solution was filtered, and the filtrate was poured into methanol (2 l) to precipitate the polylactide, which was filtered off and dried under vacuum at 40°C for 24 hours, then at 80°C for 24 hours. All the polylactides so produced were soluble in chloroform and dioxan, and polylactides 1 to 9 in the following Table were soluble in benzene, but polylactides 10 to 13 were insoluble in benzene.

40 The following particular polylactides were prepared by this method:—

45

50

55

60

65

	Ex.	D,L lactide (L) (g)	Glycolide (G) (g)	L/G Molar proportion	D,L- lactic acid	Intrinsic viscosity (dl/g)	M _w (approx.)
5	1	42.0	0	100/0	0	1.385	440,000
	2	33.5	9.0	75/25	0	1.084	400,000
10	3	32.4	8.7	75/25	920 μl	0.108*	low
	4	30.0	12.1	67/33	0	0.97	370,000
	5	30.0	12.1	67/33	0	0.94	214,000
15	6	30.0	12.1	67/33	30 μl	0.67	107,000
	7	30.0	12.1	67/33	60 μl	0.51	63,000
20	8	30.0	12.1	67/33	120 μl	0.37	33,000
	9	30.0	12.1	67/33	920 μl	0.121*	low
	10	23.0	18.5	50/50	0	1.045	300,000
25	11	23.0	18.5	50/50	400 μl	0.25	15,200
	12	23.0	18.5	50/50	920 μl	0.126*	low
30	13	23.0	18.5	50/50	1380 μl	0.108*	low

M_w are relative to polystyrene standard

* are reduced specific viscosities of a 1 g/100 ml solution in chloroform.

Alternatively, the lactide, glycolide and lactic acid if present, may be heated at 160°C and 0.08 g of
35 stannous octanoate then added to initiate the polymerisation.

Example 14

Example 14
A polylactide comprising equimolar proportions of glycolic acid and D,L-lactic acid units, and having an intrinsic viscosity of 1.36 (50 mg) was dissolved in dioxan (1 ml), and 50 μ l of a solution of ICl_3 1.18630,



(233 mg per ml of the acetate salt, equivalent to 200 mg per ml of base) in distilled water was added. The resultant hazy solution was cast as a film, the solvents were evaporated in a stream of nitrogen in the dark, and the film was dried at 40°C under reduced pressure [0.027 mbar (0.02 mm of mercury)] for 48 hours. The mixture, containing ~17% by weight of ICI.118630 in the polylactide was homogenized by three successive compression mouldings at 110°C for 10 seconds, and was finally compression moulded into implants 0.038 cm thick, each weighing 1.5 mg and containing 309±7 µg (~17% by weight) of ICI.118630.

The continuous release of ICI.118630 from such implants was demonstrated by placing them in female rats exhibiting normal oestrous behaviour. After implantation, the rats went into a period of dioestrus, detected by the lack of cornified vaginal smears, lasting from 31 to 40 days, thus indicating that ICI.118630 was being continuously released during that period.

The process described above was repeated, using 50 μ l of ICI.118630 acetate solution (150 mg of pure peptide per ml of water) and implants were made similarly, weighing 2 mg, containing 306 ± 6 μ g of ICI.118630 (13% by weight), and 0.038 cm in thickness. In the rat oestrus test described above, these implants released ICI.118630 continuously over a period of 30 to 38 days, as evidenced by the period of dioestrus in the rats.

For use in human therapy, implants containing 1 to 100 mg of ICI 118630 (5—50% by weight), weighing 2 mg—1 g, and in the form of cylindrical rods suitable for implantation by trochar, were manufactured by the process described above.

Example 15

The process described in Example 14 was repeated, but using polylactides comprising equimolar proportions of D,L-lactic acid and glycolic acid units, and having intrinsic viscosities of 0.33 and 0.25, instead of 1.36, to prepare implants containing 10% by weight of ICI.118630, weighing about 3 mg, and 0.08 cm thick.

These implants were placed in female rats (5 per group) which, prior to implantation, exhibited regular oestrous behaviour. The implants prepared from polylactide of intrinsic viscosity 0.33 exhibited an induction period of 5 days followed by a dioestrus period of about 26 days; and the implants prepared from polylactide of intrinsic viscosity 0.25 exhibited an induction period of 3—4 days, followed by a dioestrus period of about 25 days.

Similar implants, but containing 20% by weight of ICI.118630 were prepared in the same way, and these exhibited a similar dioestrus period, but no induction period, in the rat test described above.

For use in human therapy, implants containing 1 to 100 mg of ICI.118630 (5—50% by weight), weighing 2 mg—1 g, and in the form of cylindrical rods suitable for implantation by trochar were manufactured similarly.

Example 16

The process described in Example 14 was repeated, using a polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units, and having intrinsic viscosity of 1.36, to prepare mixtures of ICI.118630 and polylactide containing 3% and 1% by weight of ICI.118630. The mixture was micronised at room temperature in an ultracentrifuge mill fitted with a 125 μ m (120-mesh) screen, and the micronised particles were suspended in propylene glycol for injection at a concentration of 100 mg per ml.

Female rats showing regular oestrous behaviour were injected subcutaneously with 0.1 ml of the 3% by weight propylene glycol suspension described above, or with 0.3 ml of the 1% suspension. Both groups were monitored, by examining vaginal smears daily for cornification, and exhibited occasional cornified smears up to 20 to 24 days after dosing, followed by a clear dioestrus period up to days 38 to 42 after dosing, thus demonstrating continuous release of ICI.118630 over that period.

Example 17

Tetragastrin hydrochloride, (Trp-Met-Asp-Phe-NH₂ · HCl), (200 mg) was dissolved in a mixture of dioxan (9 ml) and water (1 ml), and to the solution was added a polylactide as described in Example 11 (1.8 g). The mixture was cast as a film, and the solvents were evaporated in a stream of nitrogen. The resulting film was dried under reduced pressure [0.027 mbar (0.02 mm of mercury)] at 40°C for 48 hours, then homogenised by three successive compression mouldings at 80°C for 10 seconds, and moulded to give films of thickness 0.02, 0.06 or 0.12 cm, each weighing about 80 mg.

The release of tetragastrin was measured by placing a film in distilled water, removing a sample of the distilled water daily, replacing all the remaining distilled water by fresh, and measuring the ultraviolet absorption of the daily samples at 277 nm. The following results were obtained, which demonstrated continuous release of tetragastrin from films of all three thicknesses:—

Time (days)	Cumulative % tetragastrin released		
	0.02 cm film	0.06 cm film	0.12 cm film
1	9.6	5.6	4.0
4	14.9	10.5	9.0
7	20.3	13.9	11.7
9	25.3	17.7	14.8
11	33.1	22.6	19.4
14	48.6	33.2	28.1
17	61.9	45.9	40.5
21	74.7	59.8	53.2
24	81.8	68.1	60.2
28	85.2	74.9	66.4
31	86.9	77.7	70.9
36	88.5	82.5	77.5
39	89.2	85.1	82.6

Example 18

Tetragastrin hydrochloride (40 mg) was dissolved in aqueous dioxan (1:9 by volume), and added to a solution of:

(a) a polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units, and having a reduced specific viscosity of 0.115 (as a 1 g/100 ml solution in chloroform), (120 mg), and

(b) a polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid residues, and having an intrinsic viscosity of 1.08 (40 mg), in dioxan (2 ml). The mixed solutions were cast as a film, as described in Example 14, and moulded as implants weighing about 50 mg, and 0.02 cm thick.

The release of tetragastrin from these implants was measured by the procedure described in Example 17, and the following results showing continuous release were obtained:—

Time (days)	Cumulative % tetragastrin released
1	0.6
2	1.0
3	1.6
4	2.7
7	8.6
10	17.2
14	29.4
18	43.1
23	56.3
28	64.9
32	71.2
36	79.0
39	83.9
44	90.5

Example 19

A polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units, and having an inherent viscosity of 0.11 as a 1 g/100 ml solution in chloroform, (50 mg), was dissolved in dioxan (1 ml) and a solution of mouse epidermal growth factor (EGF, 0.05 mg) in water 0.05 ml) was added. The mixture was cast as a film on polytetrafluoroethylene cloth, and the solvent was removed in a stream of nitrogen in the dark. The film was dried at 60°C, under reduced pressure [0.11 mbar (0.8 mm of mercury)] for 48 hours. The film was then compression moulded at 120°C for 10 seconds to give implants 0.02 cm thick, weighing 10 mg.

The implants were each placed in a black vial at 37°C with 1 ml of McIlvain's buffer (pH 7.4), (Documenta Geigy, Scientific Tables, edited by K. Diem and C. Leutner, published by J. R. Geigy SA, Basle, Switzerland, 7th Edition, 1970, page 280), containing 0.02% by weight of sodium azide. The buffer was removed daily, and replaced with fresh, and the EGF released into the buffer by the implant was measured by radio-immuno assay, which demonstrated that release started immediately, and continued for at least 2 weeks releasing 100—200 µg per day.

Example 20

A polylactide comprising equimolar proportions of D,L-lactide and glycolide and having a reduced specific viscosity (1 g/100 ml solution in chloroform) of 0.11, (400 mg), was dissolved in dioxan (2 ml), and a solution/suspension of bovine prolactin (100 mg) in distilled water (0.5 ml) was added, with vigorous agitation. The mixture was poured onto a polytetrafluoroethylene cloth, and dried, first in a stream of nitrogen and then under reduced pressure [0.013 mbar (0.01 mm of mercury)] at 40°C for 24 hours. The

0 058 481

heterogeneous mixture thus obtained was homogenised by four successive compression mouldings at 60°C, and then moulded into a slab 0.2 cm thick, from which implants weighing 60 mg were excised.

The implants were placed subcutaneously into adult female rats, which were then periodically bled from the tail, and the prolactin in the blood samples thus obtained was measured by radio-immune assay.

5 A placebo group, receiving no prolactin in the implant, was similarly assayed, and the levels of circulating prolactin compared. The following results were obtained:—

10	Time	Plasma level of bovine prolactin (µg/ml)	
		Placebo group	Treatment group
	1	0.38	24.7
15	2	0.45	105.9
	6	0.54	7.7
	9	0.72	17.8
20	13	0.52	65.4
	16	0.56	89.7
25	20	0.75	288
	23	0.81	142
	26	0.84	562
30	42	1.25	1250

Example 21

35 The process described in Examples 1—13 was repeated, except that the polylactide was dissolved in dioxan instead of in chloroform, and similar polylactides were obtained.

Examples 22—29

40 The process described in Examples 1—13 was repeated, except that the polylactide was dissolved in glacial acetic acid, and the glacial acetic acid solution thus obtained was added dropwise to methanol in order to precipitate the polylactide, which was filtered off and dried under vacuum at 40°C for 24 hours, then at 80°C for 24 hours.

The following particular polylactides were prepared by this method:—

45

50

55

60

65

Ex.	D,L-lactide (L) (g)	Glycolide (G) (g)	L/G Molar proportion	D,L-lactic acid	Intrinsic viscosity	Mw. (approx.)	Stannous octanoate
22	33.3	26.7	50/50	360 µl	0.234	13,500	93 µl
23	11.1	8.9	50/50	120 µl	0.243	14,450	31 µl
24	11.1	8.9	50/50	120 µl	0.265	16,800	31 µl
25	111.0	89.0	50/50	1.2 ml	0.257	15,850	0.31 ml
26	111.0	89.0	50/50	1.2 ml	0.239	14,200	0.31 ml
27	88.8	71.2	50/50	0.96 ml	0.262	16,600	0.25 ml
28	22.2	17.8	50/50	1.38 ml	0.09*		62 µl
29	20.0	—	100/0	0.12 ml	0.260	16,200	31 µl

* Inherent viscosity as 1 g/100 ml solution in chloroform.

Example 30

A polylactide comprising equimolar proportions of glycolic acid and D,L-lactic acid units and having an intrinsic viscosity of 0.25 was dissolved in glacial acetic acid, and the solution was freeze-dried. The freeze dried powder (540.7 mg) and ICI 118630 (142.1 mg) of the acetate salt (equivalent to >124 mg of base) were dissolved in 6.8 ml of acetic anhydride-free glacial acetic acid and freeze dried for 24 h.

(The glacial acetic acid was refluxed for 2 h with 1% water to remove the acetic anhydride): The freeze dried product was extruded under pressure at 70°C to a 1 mm diameter rod, from which implants of the required weight were cut. The implants were dissolved in an appropriate solvent, for example acetonitrile, and assayed for drug content and purity. Implants were shown to contain 16.1% w/w pure 118630 base.

Release of 118630 was evaluated by immersing implants weighing approximately 10 mg in McIlvains pH 7.4 buffer at 37°C. ICI 118630 was released continuously for at least 5 weeks.

In a further experiment, implants weighing approximately 390 µg, 860 µg, 1500 µg, 3000 µg and ~6000 µg were implanted subcutaneously in groups of adult, regularly cycling female rats. In the 28 days following implantation, animals were essentially free of oestrus intervals showing that active drug was released continuously over this period.

Example 31

A solution of ICI 118630 acetate salt was prepared by dissolving 170.8 mg of ICI 118630 acetate in 5 ml of acetic anhydride-free glacial acetic acid. (The glacial acetic acid was fluxed for 2 h with 1% water to remove acetic anhydride). This solution was shown by high pressure liquid chromatography (HPLC), to contain 25.21 mg of ICI 118630 base per ml, 442.5 mg of polylactide (prepared as in Example 25 was dissolved in 4.5 ml of the acetic acid solution, and the resulting solution was freeze dried for 25 h. The freeze dried product was extruded under pressure at 74°C to a 1 mm diameter rod, from which implants of the required weight were cut. The implants were dissolved in an appropriate solvent, such as acetonitrile, and the resulting solution was analysed by HPLC. The implants were shown to contain 20% w/w pure 118630 base.

Example 32

A polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units and having a reduced specific viscosity of 0.126 (1 g/100 ml solution in chloroform), (240 mg), was dissolved in glacial acetic acid (5 ml) and a solution of tetragastrin hydrochloride (60 mg) dissolved in glacial acetic acid (5 ml) was added with vigorous agitation. The solution was freeze dried for 24 h and the resultant solid was compression moulded at 50°C for 20 seconds to give implants 0.2 cm thick and weighing 35—40 mgs.

The above procedure was repeated with the following polymers:—

(a) a polylactide comprising 67 mole % of D,L-lactic acid and 33 mole% glycolic acid units and having a reduced specific viscosity of 0.121 (1 g/100 ml solution in chloroform).

(b) a polylactide comprising 75 mole % of D,L-lactic acid and 25 mole % glycolic acid units and having a reduced specific viscosity of 0.108 (1 g/100 ml solution in chloroform).

(c) a polylactide comprising 100% of D,L-lactic acid and having a reduced specific viscosity of 0.100 (1 g/100 ml solution of chloroform).

The release of tetragastrin from these implants was measured by the procedure described in Example 17, and the following results were obtained:—

Time (days)	Cumulative % tetragastrin released			
	50% D,L-lactide 50% glycolide	67% D,L-lactide 33% glycolide	75% D,L-lactide 25% glycolide	100% D,L-lactide
1	6.0	1.0	1.7	1.9
3	12.9	2.1	3.2	3.0
7	23.3	7.1	8.0	5.1
9	27.2	12.2	11.6	6.5
11	30.3	20.2	15.8	8.2
15	36.7	40.0	27.0	14.0
17	39.3	45.0	29.7	17.9
21	44.5	51.8	35.1	25.5
24	49.6	55.6	37.9	30.4
28	58.8	59.6	41.1	36.1
31	68.8	62.3	42.8	40.1
35	81.5	67.3	45.0	45.6
39	91.0	74.3	47.6	50.7
42	95.9	81.9	50.6	55.3
46	96.5	89.1	55.5	60.4
49	97.5	93.2	60.0	65.2
53		95.4	64.8	70.0
56		96.3	68.6	73.6
59		97.0	73.1	77.8
63		97.2	77.1	81.5
70			82.7	86.1
74			85.0	87.5
84			90.4	89.5

These results show that continuous release of tetragastrin is obtained using low molecular weight poly(lactides) and that duration of release is determined by the composition of the hydrolytically unstable polyester.

Example 33

A polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units and having an inherent viscosity of 0.126 (as a 1 g/100 ml solution in chloroform) (9.5 mg), was dissolved in distilled dioxan (0.25 ml) and a solution of mouse epidermal growth factor (EGF 0.5 mg) in distilled water (0.1 ml) was added. The mixture was cast as a film on polytetrafluoroethylene cloth, and the solvent was removed in a stream of nitrogen, in the dark. The film was dried at 40°C under reduced pressure [0.013 mbar (0.01 mm of mercury)] for 48 hrs. The film was then compression moulded at 70°C for 10 seconds to an implant 0.02 cm thick, weighing about 9 mg. A placebo implant was also prepared.

The samples were implanted subcutaneously into carotid cannulated guinea pigs, blood samples taken periodically and the plasma EGF levels were measured by radio-immuno assay.

Raised plasma EGF levels were observed from Day 3 and continued for at least 1 week.

- Similar implants were prepared as described above, but using a polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units and having an intrinsic viscosity of 1.06. Compression moulding of this implant was done at 120°C.

Implantation and plasma assays were done as described above, but raised plasma EGF levels were not observed until day 17 after implantation.

10 Example 34

- A polylactide comprising equimolar proportions of D,L-lactic acid and glycolic acid units and having an inherent viscosity of 0.093 as a 1 g/100 ml solution in chloroform (40 mg) was dissolved in anhydrous-free glacial acetic acid (1 ml) and a solution of mouse epidermal growth factor (EGF, 8.15 mg) in a mixture of water (0.5 ml) and anhydride-free glacial acetic acid (3 ml) was added. The solution was freeze-dried for 24 h. The resulting powder was then compression moulded at 50°C to give an implant 2 mm×2 mm×10 mm weighing 36.1 mg.

The sample was implanted subcutaneously into a cannulated cat, blood samples were taken periodically and the plasma EGF levels were measured by radio-immuno assay.

Raised plasma EGF levels were observed from day 3 and continued for at least 40 days.

20 Example 35

Implants containing bovine prolactin were prepared as described in Example 20, but using:—

- (a) a polylactide (400 mg) comprising equimolar proportions of D,L-lactic acid and glycolic acid units and having a reduced specific viscosity (1 g/100 ml solution in chloroform) of 0.11, dissolved in 4 ml dioxan; and

- (b) a polylactide (400 mg) comprising equimolar proportions of D,L-lactic acid and glycolic acid units and having an intrinsic viscosity of 1.06 dissolved in 4 ml dioxan. This sample was moulded at 110°C.

- Formulations (a) and (b) were each tested *in vivo* as described in Example 20. Formulation (a) released significant levels of plasma bovine prolactin from at least as early as day 4 and continued to release for at least 85 days, while formulation (b) released significant levels from at least as early as day 8 for at least 85 days.

Claims

1. A pharmaceutical composition comprising a polylactide, which is a polymer of lactic acid alone, a copolymer of lactic and glycolic acids, a mixture of such polymers, a mixture of such copolymers or a mixture of such polymers and copolymers, and an acid-stable polypeptide, which is not significantly hydrolysed under the conditions encountered within the composition during the period of use envisaged, which composition, when placed in an aqueous physiological-type environment, releases the polypeptide into the aqueous physiological-type environment in continuous manner, giving a release profile which is essentially monophasic, although it may have a point of inflection, but certainly has no "plateau" phase, over a period of at least one week; but excluding a composition in microcapsule form comprising at least one polypeptide which is a naturally occurring luteinising hormone releasing hormone (LH—RH), a synthetically prepared material of the same type or synthetically prepared analogues of naturally occurring LH—RH which act in some manner on the anterior pituitary gland to affect the release of luteinising hormone (LH) and follicle stimulating hormone (FSH).

2. A pharmaceutical composition, comprising a polylactide, which is a polymer of lactic acid alone, a copolymer of lactic and glycolic acids, a mixture of such polymers, a mixture of such copolymers or a mixture of such polymers and copolymers, and an acid-stable polypeptide, which is not significantly hydrolysed under the conditions encountered within the composition during the period of use envisaged, which composition, when placed in an aqueous physiological-type environment, exhibits two successive phases of release of the polypeptide, the first phase being released by matrix diffusion and the second phase being released consequent upon degradation of the polylactide, characterised in that the diffusion phase and the degradation-induced phase overlap in time, and release of polypeptide occurs over a period of at least one week; but excluding a composition in microcapsule form comprising at least one polypeptide which is a naturally occurring luteinising hormone releasing hormone (LH—RH), a synthetically prepared material of the same type or synthetically prepared analogues of naturally occurring LH—RH which act in some manner on the anterior pituitary gland to affect the release of luteinising hormone (LH) and follicle stimulating hormone (FSH).

3. A pharmaceutical composition, comprising a polylactide, which is a polymer of lactic acid alone, a copolymer of lactic and glycolic acids, a mixture of such polymers, a mixture of such copolymers or a mixture of such polymers and copolymers, and an acid-stable polypeptide, which is not significantly hydrolysed under the conditions encountered within the composition during the period of use envisaged, which composition, when placed in an aqueous physiological-type environment, absorbs water in a continuous manner, giving a water absorption profile which is essentially monophasic, although it may

have a point of inflection, but certainly no "plateau" phase, until the polylactide has been degraded and essentially all of the polypeptide has been released into the aqueous physiological-type environment, over a period of at least one week; but excluding a composition in microcapsule form comprising at least one polypeptide which is a naturally occurring luteinising hormone releasing hormone (LH—RH), a
 5 synthetically prepared material of the same type or synthetically prepared analogues of naturally occurring LH—RH which act in some manner on the anterior pituitary gland to affect the release of luteinising hormone (LH) and follicle stimulating hormone (FSH).

4. A pharmaceutical composition as claimed in claim 1, 2 or 3 wherein the acid-stable polypeptide is oxytocin, vasopressin, adrenocorticotrophic hormone (ACTH), epidermal growth factor (EGF), prolactin,
 10 luliberin or luteinizing hormone releasing hormone (LH—RH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, renin, bradykinin, tyrocidin, gramicidines, and synthetic analogues and modifications and pharmacologically-active fragments thereof.

5. A pharmaceutical composition as claimed in claim 1, 2 or 3 wherein the polylactide has a high degree of heterogeneity, in respect of glycolide-rich and lactide-rich molecules, as evidenced by the glycolic acid carbonyl carbon signal in the ¹³C n.m.r. spectrum appearing as other than a pair of doublets, or of high polydispersity.

6. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 5 to 50% by weight of a polypeptide of molecular weight less than 2000 and from 50 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.5 to 3, and which has an inherent viscosity of greater than 0.5 dl/g
 20 (1 g per 100 ml in chloroform or dioxan).

7. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 5 to 50% by weight of a polypeptide of molecular weight less than 2000, and from 50 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.2 to 3, and which has an inherent viscosity of 0.2 to 0.5 dl/g
 25 (1 g per 100 ml in chloroform or dioxan).

8. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 0.1 to 50% by weight of a polypeptide of molecular weight less than 2000 and from 50 to 99.9% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0 to 3, and which has an inherent viscosity of less than 0.2 dl/g
 (1 g per 100 ml in chloroform or dioxan).

9. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 10 to 50% by weight of a polypeptide of molecular weight 1,500 to 10,000 and from 50 to 90% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.5 to 3, and which has an inherent viscosity of 0.4 to 0.8 dl/g
 30 (1 g per 100 ml in chloroform or dioxan).

10. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 5 to 30% by weight of a polypeptide of molecular weight 1,500 to 10,000 and from 70 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.2 to 3, and which has an inherent viscosity of 0.15 to 0.4 dl/g
 35 (1 g per 100 ml in chloroform or dioxan).

11. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 0.1 to 20% by weight of a polypeptide of molecular weight 1,500 to 10,000 and from 80 to 99.9% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0 to 3, and which has an inherent viscosity of less than
 40 0.15 dl/g (1 g per 100 ml in chloroform or dioxan).

12. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 0.1 to 50% by weight of a polypeptide of molecular weight 8,000 to 30,000 and from 50 to 99.9% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0 to 3, and which has an inherent viscosity of 0.15 to
 45 0.4 dl/g (1 g per 100 ml in chloroform or dioxan).

13. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 10 to 50% by weight of a polypeptide of molecular weight 8,000 to 30,000 and from 50 to 90% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.7 to 3, and which has an inherent viscosity of 0.1 to 0.15 dl/g
 (1 g per 100 ml in chloroform or dioxan).

14. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 0.1 to 50% by weight of a polypeptide of molecular weight 8,000 to 30,000 and from 50 to 99.9% by weight of a polylactide, wherein the ratio of glycolide to lactide units is from 0 to 3, and which has an inherent viscosity of less than
 50 0.1 dl/g (1 g per 100 ml in chloroform or dioxan).

15. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 5 to 50% by weight of
 55 ICI.118,630

(Pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

and from 50 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.8 to 3, and which has an inherent viscosity of more than 0.5 dl/g (1 g per 100 ml in chloroform or dioxan).

60 16. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 5 to 50% by weight of ICI.118,630

(pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

and from 50 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.2 to 3, and which has an inherent viscosity of 0.2 to 0.5 dl/g (1 g per 100 ml in chloroform or dioxan).
 65

17. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 0.1 to 50% by weight of ICI.118,630

(pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

and from 50 to 99.9% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0 to 3, and which has an inherent viscosity of less than 0.2 dl/g (1 g per 100 ml in chloroform or dioxan).

18. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 10 to 50% by weight of epidermal growth factor or urogastrone and from 50 to 90% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.5 to 3, and which has an inherent viscosity of 0.4 to 0.8 dl/g (1 g per 100 ml in chloroform or dioxan).

19. A pharmaceutical composition as claimed in claim 1, 2 or 3 comprising from 0.1 to 50% by weight of epidermal growth factor or urogastrone and from 50 to 99.9% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0 to 3, and which has an inherent viscosity of 0.15 to 0.4 dl/g (1 g per 100 ml in chloroform or dioxan).

20. A pharmaceutical composition in the form of a suspension for injection comprising from 1 to 50% by weight of a solid formulation, which itself comprises from 0.1 to 50% by weight of an acid-stable polypeptide which is not significantly hydrolysed under the conditions encountered within the composition during the period of use envisaged, and from 50 to 99.9% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0 to 3 and which is either soluble in benzene and has an inherent viscosity (1 g/100 ml solution in benzene) of less than 0.5 dl/g or is insoluble in benzene and has an inherent viscosity (1 g/100 ml solution in chloroform or dioxan) of less than 4 dl/g which solid formulation has been reduced to fine particle size, together with from 50 to 99% by weight of a liquid carrier suitable for injection into mammals.

21. A polymer containing lactic acid and optionally glycolic acid units comprising from 25 to 100% molar of lactic acid units and from 0 to 75% molar of glycolic acid units, and which has an inherent viscosity (1 g/100 ml solution in chloroform or dioxan) equal to or greater than 0.09 and an intrinsic viscosity equal to or less than 0.33.

22. A process for the manufacture of a polymer or copolymer as claimed in claim 21 which comprises the ring-opening polymerisation of the cyclic dimer of the lactic acid, optionally in the presence of the cyclic dimer of glycolic acid, at elevated temperature in the presence of a polymerisation catalyst selected from the zinc oxide, zinc carbonate, basic zinc carbonate, diethyl zinc, organotin compounds, tributylaluminium, titanium, magnesium or barium compounds or lithium, and in the presence of a chain-stopping agent.

35 Patentansprüche

1. Pharmazeutische Zusammensetzung, die enthält: ein Polylactid, das ein Polymer von Milchsäure alleine, ein Copolymer von Milch- und Glycolsäure, ein Gemisch aus solchen Polymeren, ein Gemisch aus solchen Copolymeren oder ein Gemisch aus solchen Polymeren und Copolymeren ist, und ein säurestabiles Polypeptid, das unter den Bedingungen, die innerhalb der Zusammensetzung während der vorgesehenen Anwendungsdauer herrschen, nicht wesentlich hydrolysiert wird, wobei die Zusammensetzung, wenn sie in eine wäßrige Umgebung physiologischer Art gebracht wird, das Polypeptid während eines Zeitraums von mindestens einer Woche in die wäßrige Umgebung physiologischer Art in kontinuierlicher Weise mit einem Profil abgibt, das im wesentlichen monophasisch ist, zwar einen Wendepunkt aufweisen kann, aber keinesfalls eine "Plateau"-Phase besitzt, wobei jedoch eine Zusammensetzung in Mikrokapselform ausgeschlossen ist, die wenigstens ein Polypeptid enthält, das ein natürlich vorkommendes luteinisierendes Hormon freisetzendes Hormon(LH—RH), ein synthetisch hergestelltes Material des gleichen Typs oder synthetisch hergestellte Analoge von natürlich vorkommendem LH—RH, die in irgendeiner Weise auf die Hirnanhangsdrüse einwirken, um die Freisetzung von luteinisierendem Hormon (LH) und follikelstimulierendem Hormon (FSH) zu bewirken, ist.

2. Pharmazeutische Zusammensetzung, die enthält: ein Polylactid, das ein Polymer von Milchsäure alleine, ein Copolymer von Milch- und Glycolsäure, ein Gemisch aus solchen Polymeren, ein Gemisch aus solchen Copolymeren oder ein Gemisch aus solchen Polymeren und Copolymeren ist, und ein säurestabiles Polypeptid, das unter den Bedingungen, die innerhalb der Zusammensetzung während der vorgesehenen Anwendungsdauer herrschen, nicht wesentlich hydrolysiert wird, wobei die Zusammensetzung, wenn sie in eine wäßrige Umgebung physiologischer Art gebracht wird, zwei aufeinanderfolgende Phasen der Abgabe des Polypeptids zeigt, von denen die erste Phase eine Abgabe durch Matrixdiffusion und die zweite Phase eine Abgabe als Folge des Abbaus des Polylactids ist, dadurch gekennzeichnet, daß die Diffusionsphase und die durch Abbau veranlaßte Phase sich zeitlich überlappen und daß die Abgabe des Polypeptids während eines Zeitraums von mindestens einer Woche erfolgt, wobei jedoch eine Zusammensetzung in Mikrokapselform ausgeschlossen ist, die wenigstens ein Polypeptid enthält, das ein natürlich vorkommendes, luteinisierendes Hormon freisetzendes Hormon (LH—RH), ein synthetisch hergestelltes Material des gleichen Typs oder synthetisch hergestellte Analoge von natürlich vorkommendem LH—RH, die in irgendeiner Weise auf die Hirnanhangsdrüse einwirken, um die Freisetzung von luteinisierendem Hormon (LH) und follikelstimulierendem Hormon (FSH) zu bewirken, ist.

3. Pharmazeutische Zusammensetzung, die enthält: ein Polylactid, das ein Polymer von Milchsäure alleine, ein Copolymer von Milch- und Glycolsäure, ein Gemisch aus solchen Polymeren, ein Gemisch aus solchen Copolymeren oder ein Gemisch aus solchen Polymeren und Copolymeren ist, und ein säurestabiles Polypeptid, das unter den Bedingungen, die innerhalb der Zusammensetzung während der vorgesehenen Anwendungsdauer herrschen, nicht wesentlich hydrolysiert wird, wobei die Zusammensetzung, wenn sie in eine wäßrige Umgebung physiologischer Art gebracht wird, Wasser während eines Zeitraums von mindestens einer Woche in kontinuierlicher Weise mit einem Profil absorbiert, das im wesentlichen monophasisch ist, zwar einen Wendepunkt aufweisen kann, aber keinesfalls eine "Plateau"-Phase besitzt, bis das Polylactid abgebaut und im wesentlichen das gesamte Polypeptid in die wäßrige Umgebung physiologischer Art abgegeben worden ist, wobei jedoch eine Zusammensetzung in Mikrokapselform ausgeschossen ist, die wenigstens ein Polypeptid enthält, das ein natürlich vorkommendes, luteinisierendes Hormon freisetzendes Hormon (LH—RH), ein synthetisch hergestelltes Material des gleichen Typs oder synthetisch hergestellte Analoge von natürlich vorkommendem LH—RH, die in irgendeiner Weise auf die Hirnanhangsdrüse einwirken, um die Freisetzung von luteinisierendem Hormon (LH) und follikelstimulierendem Hormon (FSH) zu bewirken, ist.
4. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, bei welcher das säurestabile Polypeptid aus Oxytocin, Vasopressin, adrenocorticotrophem Hormon (ACTH), epidermalem Wachstumsfaktor (EGF), Prolactin, Luliberin oder Hormon, das luteinisierendes Hormon abgibt (LH—RH), Insulin, Somatostatin, Glucagon, Interferon, Gastrin, Tetragastrin, Pentagastrin, Urogastron, Secretin, Calcitonin, Enkephalinen, Endorphinen, Angiotensinen, Renin, Bradykinin, Tyrocidin, Gramicidinen und synthetischen Analogon und Modifikationen und pharmakologisch aktiven Fragmenten davon besteht.
5. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, bei welcher das Polylactid einen hohen Grad von Heterogenität hinsichtlich glycolidreicher und lactidreicher Moleküle, was durch das Auftreten des Glycolsäure-Carbonylkohlenstoff-Signals im ^{13}C -NMR-Spektrum in anderer Form als einem Dublettenpaar angezeigt wird, oder eine hohe Polydispersität aufweist.
6. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 5 bis 50 Gew.-% eines Polypeptids mit einem Molekulargewicht von weniger als 2000 und 50 bis 95 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0,5 bis 3 beträgt und welches eine inhärente Viskosität von mehr als 0,5 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
7. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 5 bis 50 Gew.-% eines Polypeptids mit einem Molekulargewicht von weniger als 2000 und 50 bis 95 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0,2 bis 3 beträgt und welches eine inhärente Viskosität von 0,2 bis 0,5 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
8. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 0,1 bis 50 Gew.-% eines Polypeptids mit einem Molekulargewicht von weniger als 2000 und 50 bis 99,9 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0 bis 3 beträgt und welches eine inhärente Viskosität von weniger als 0,2 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
9. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 10 bis 50 Gew.-% eines Polypeptids mit einem Molekulargewicht von 1500 bis 10 000 und 50 bis 90 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0,5 bis 3 beträgt und welches eine inhärente Viskosität von 0,4 bis 0,8 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
10. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 5 bis 30 Gew.-% eines Polypeptids mit einem Molekulargewicht von 1500 bis 10 000 und 70 bis 95 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0,2 bis 3 beträgt und welches eine inhärente Viskosität von 0,15 bis 0,4 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
11. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 0,1 bis 20 Gew.-% eines Polypeptids mit einem Molekulargewicht von 1500 bis 10 000 und 80 bis 99,9 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0 bis 3 beträgt und welches eine inhärente Viskosität von weniger als 0,15 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
12. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 0,1 bis 50 Gew.-% eines Polypeptids mit einem Molekulargewicht von 8000 bis 30 000 und 50 bis 99,9 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0 bis 3 beträgt und welches eine inhärente Viskosität von 0,15 bis 0,4 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
13. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 10 bis 50 Gew.-% eines Polypeptids mit einem Molekulargewicht von 8000 bis 30 000 und 50 bis 90 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0,7 bis 3 beträgt und welches eine inhärente Viskosität von 0,1 bis 0,15 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
14. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 0,1 bis 50 Gew.-% eines Polypeptids mit einem Molekulargewicht von 8000 bis 30 000 und 50 bis 99,9 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0 bis 3 beträgt und welches eine inhärente Viskosität von weniger als 0,1 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.
15. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 5 bis 50 Gew.-% ICI 118 630

(Pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

und 50 bis 95 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0,8 bis 3 beträgt und welches eine inhärente Viskosität von mehr als 0,5 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.

16. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 5 bis 50 Gew.-% ICI 118 630

(Pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

und 50 bis 95 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0,2 bis 3 beträgt und welches eine inhärente Viskosität von 0,2 bis 0,5 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.

17. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 0,1 bis 50 Gew.-% ICI 118 630

(Pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

und 50 bis 99,9 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0 bis 3 beträgt und welches eine inhärente Viskosität von weniger als 0,2 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.

18. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 10 bis 50 Gew.-% epidermalen Wachstumsfaktor oder Urogastron und 50 bis 90 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0,5 bis 3 beträgt und welches eine inhärente Viskosität von 0,4 bis 0,8 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.

19. Pharmazeutische Zusammensetzung nach Anspruch 1, 2 oder 3, welche 0,1 bis 50 Gew.-% epidermalen Wachstumsfaktor oder Urogastron und 50 bis 99,9 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0 bis 3 beträgt und welches eine inhärente Viskosität von 0,15 bis 0,4 dl/g (1 g je 100 ml, in Chloroform oder Dioxan) besitzt.

20. Pharmazeutische Zusammensetzung in Form einer Suspension für Injektion, enthaltend 1 bis 50 Gew.-% einer festen Formulierung, die ihrerseits 0,1 bis 50 Gew.-% eines säurestabilen Polypeptids, das unter den Bedingungen, die innerhalb der Zusammensetzung während der vorgesehenen Anwendungsdauer herrschen, nicht wesentlich hydrolysiert wird, und 50 bis 99,9 Gew.-% eines Polylactids enthält, bei welchem das Verhältnis von Glycolid- zu Lactideinheiten 0 bis 3 beträgt und welches entweder in Benzol löslich ist und eine inhärente Viskosität (1 g je 100 ml Lösung in Benzol) von weniger als 0,5 dl/g besitzt oder in Benzol unlöslich ist und eine inhärente Viskosität (1 g je 100 ml Lösung in Chloroform oder Dioxan) von weniger als 4 dl/g besitzt, wobei die feste Formulierung auf eine feine Teilchengröße zerteilt worden ist, zusammen mit 50 bis 99 Gew.-% eines flüssigen Trägers, der sich für Injektion in Säuger eignet.

21. Polymer aus Milchsäure- und gegebenenfalls Glycolsäureeinheiten, welches 25 bis 100 Mol% Milchsäureeinheiten und 0 bis 75 Mol% Glycolsäureeinheiten enthält und welches eine inhärente Viskosität (1 g je 100 ml Lösung in Chloroform oder Dioxan) von 0,09 oder mehr und eine intrinsische Viskosität von 0,33 oder weniger besitzt.

22. Verfahren zur Herstellung eines Polymers oder Copolymers nach Anspruch 21, bei welchem das cyclische Dimer von Milchsäure gegebenenfalls in Anwesenheit des cyclischen Dimers von Glycolsäure bei einer erhöhten Temperatur in Gegenwart eines Polymerisationskatalysators, der aus Zinkoxid, Zinkcarbonat, basischem Zinkcarbonat, Diethylzink, Organozinnverbindungen, Tributylaluminium, Titan-, Magnesium- oder Bariumverbindungen oder Bleiglätte ausgewählt ist, und in Gegenwart eines Kettenabbruchmittels der ringöffnenden Polymerisation unterworfen wird.

Revendications

1. Composition pharmaceutique comprenant un polylactide, qui est un polymère de l'acide lactique seul, un copolymère de l'acide lactique et de l'acide glycolique, un mélange de ces polymères, un mélange de ces copolymères ou un mélange de ces polymères et copolymères, et un polypeptide stable aux acides, qui n'est pas notablement hydrolysé dans les conditions auxquelles la composition est exposée pendant la période d'utilisation envisagée, composition qui, lorsqu'elle est placée dans un environnement aqueux de type physiologique, libère le polypeptide dans l'environnement aqueux de type physiologique d'une manière continue, en donnant un profil de libération qui comporte essentiellement une seule phase, bien qu'il puisse avoir un point d'inflexion, mais ne comprend à coup sûr aucune phase en "palier", en une période d'au moins une semaine; mais à l'exclusion d'une composition sous forme de microcapsules comprenant au moins un polypeptide qui est une hormone libérant l'hormone lutéinisante (LH—RH) naturelle, une matière du même type préparée par synthèse ou des analogues, préparés par synthèse, de l'hormone LH—RH naturelle qui agissent d'une certaine manière sur le lobe antérieur de l'hypophyse pour effectuer la libération de l'hormone lutéinisante (LH) et de la gonadotrophine A (FSH).

2. Composition pharmaceutique, comprenant un polylactide, qui est un polymère de l'acide lactique seul, un copolymère, de l'acide lactique et de l'acide glycolique, un mélange de ces polymères, un mélange de ces copolymères, ou un mélange de ces polymères et copolymères, et un polypeptide stable aux acides, qui n'est pas notablement hydrolysé dans les conditions auxquelles la composition est exposée pendant la

période d'utilisation envisagée, composition qui, lorsqu'elle est placée dans un environnement aqueux de type physiologique, présente deux phases successives de libération du polypeptide, la première phase étant la libération par diffusion dans la matrice et la seconde phase étant la libération consécutive à la dégradation du polylactide, caractérisée en ce que la phase de diffusion et la phase induite par dégradation se recouvrent dans le temps, et la libération du polypeptide a lieu au cours d'une période d'au moins une semaine; mais à l'exclusion d'une composition sous forme de microcapsules comprenant au moins un polypeptide qui est une hormone libérant l'hormone lutéinisante (LH—RH) naturelle, une matière du même type, préparée par synthèse, ou des analogues, préparés par synthèse, de l'hormone LH—RH naturelle qui agissent d'une certaine manière sur le lobe antérieur de l'hypophyse pour effectuer la libération de l'hormone lutéinisante (LH) et de la gonadotrophine A (FSH).

3. Composition pharmaceutique, comprenant un polylactide qui est un polymère de l'acide lactique seul, un copolymère de l'acide lactique et de l'acide glycolique, un mélange de ces polymères, un mélange de ces copolymères ou un mélange de ces polymères et copolymères, et un polypeptide stable aux acides, qui n'est pas notablement hydrolysé dans les conditions auxquelles la composition est exposée pendant la période d'utilisation envisagée, composition qui, lorsqu'elle est placée dans un environnement aqueux de type physiologique, absorbe de l'eau d'une manière continue en donnant un profil d'absorption de l'eau qui comprend essentiellement une seule phase, bien qu'il puisse avoir un point d'inflexion, mais ne comprend à coup sûr aucune phase en "palier", jusqu'à ce que le polylactide ait été dégradé et qu'il ait été essentiellement en totalité libéré dans l'environnement aqueux de type physiologique, en une période d'au moins une semaine; mais à l'exclusion d'une composition sous forme de microcapsules comprenant au moins un polypeptide qui est une hormone libérant l'hormone lutéinisante (LH—RH) naturelle, une matière du même type préparée par synthèse ou des analogues, préparés par synthèse, de LH—RH naturelle qui agissent d'une certaine manière sur le lobe antérieur de l'hypophyse en effectuant la libération de l'hormone lutéinisante (LH) et de la gonadotrophine A (FSH).

4. Composition pharmaceutique suivant la revendication 1, 2 ou 3, dans laquelle le polypeptide stable aux acides est l'oxytocine, la vasopressine, l'hormone adrénocorticotrope (ACTH), le facteur de croissance épidermique (EGF), la prolactine, la lulibérine ou l'hormone libérant l'hormone lutéinisante (LH—RH), l'insuline, la somatostatine, le glucagon, l'interféron, la gastrine, la tétragastrine, la pentagastrine, l'urogastrone, la sécrétine, la calcitonine, les encéphalines, les endorphines, les angiotensines, la rénine, la bradykinine, la tyrocidine, les gramicidines et leurs analogues et modifications synthétiques et leurs fragments pharmacologiquement actifs.

5. Composition pharmaceutique suivant la revendication 1, 2 ou 3, dans laquelle le polylactide a un haut degré d'hétérogénéité par rapport aux molécules riches en glycolide et riches en lactide, comme mis en évidence par le signal du carbone de carbonyle de l'acide glycolique dans le spectre de résonance magnétique des noyaux de ^{13}C apparaissant autrement que comme une paire de doublets, ou une haute polydispersité.

6. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 5 à 50% en poids d'un polypeptide de poids moléculaire inférieur à 2000 et 50 à 95% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0,5 à 3 et qui a une viscosité intrinsèque supérieure à 0,5 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

7. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 5 à 50% en poids d'un polypeptide de poids moléculaire inférieur à 2000 et 50 à 95% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0,2 à 3 et qui a une viscosité intrinsèque de 0,2 à 0,5 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

8. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 0,1 à 50% en poids d'un polypeptide de poids moléculaire inférieur à 2000 et 50 à 99,9% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0 à 3 et qui a une viscosité intrinsèque inférieure à 0,2 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

9. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 10 à 50% en poids d'un polypeptide de poids moléculaire allant de 1500 à 10 000 et 50 à 90% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0,5 à 3 et qui a une viscosité intrinsèque de 0,4 à 0,8 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

10. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 5 à 30% en poids d'un polypeptide de poids moléculaire allant de 1500 à 10 000 et 70 à 95% en poids d'un polylactide dont le rapport des motifs glycoside aux motifs lactide va de 0,2 à 3 et qui a une viscosité intrinsèque de 0,15 à 0,4 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

11. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 0,1 à 20% en poids d'un polypeptide de poids moléculaire compris entre 1500 et 10 000 et 80 à 99,9% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0 à 3 et qui a une viscosité intrinsèque inférieure à 0,15 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

12. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 0,1 à 50% en poids d'un polypeptide de poids moléculaire compris entre 8000 et 30 000 et 50 à 99,9% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0 à 3, et qui a une viscosité intrinsèque de 0,15 à 0,4 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

13. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 10 à 50% en poids

d'un polypeptide de poids moléculaire compris entre 8000 et 30 000 et 50 à 90% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0,7 à 3, et qui a une viscosité intrinsèque de 0,1 à 0,15 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

14. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 0,1 à 50% en poids
5 d'un polypeptide de poids moléculaire compris entre 8000 et 30 000 et 50 à 99,9% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0 à 3 et qui a une viscosité intrinsèque inférieure à 0,1 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

15. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 5 à 50% en poids de
ICI.118 630

10

(Pyro-Glu-His-Trp-Ser-Tyr-D-Se(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

et 50 à 95% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0,8 à 3 et qui a une viscosité intrinsèque de plus de 0,5 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

16. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 5 à 50% en poids de
15 ICI.118 630

(Pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

20 et 50 à 95% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0,2 à 3 et qui a une viscosité intrinsèque de 0,2 à 0,5 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

17. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 0,1 à 50% en poids de
ICI.118 630

25

(Pyro-Glu-His-Trp-Ser-Tyr-D-Ser(O-tBu)-Leu-Arg-Pro-Azgly-NH₂)

et 50 à 99,9% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0 à 3 et qui a une viscosité intrinsèque inférieure à 0,2 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

18. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 10 à 50% en poids de
30 facteur de croissance épidermique ou d'urogastrone et 50 à 90% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0,5 à 3 et qui a une viscosité intrinsèque de 0,4 à 0,8 dl/g (1 g/100 ml) dans le chloroforme ou le dioxanne).

19. Composition pharmaceutique suivant la revendication 1, 2 ou 3, comprenant 0,1 à 50% en poids de
35 facteur de croissance épidermique ou d'urogastrone et 50 à 99,9% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0 à 3 et qui a une viscosité intrinsèque de 0,15 à 0,4 dl/g (1 g/100 ml dans le chloroforme ou le dioxanne).

20. Composition pharmaceutique sous la forme d'une suspension injectable, comprenant 1 à 50% en
poids d'une formulation solide qui comprend elle-même 0,1 à 50% en poids d'un polypeptide stable aux
40 acides qui n'est pas notablement hydrolysé dans les conditions subies au sein de la composition pendant la période de l'utilisation envisagée, et 50 à 99,9% en poids d'un polylactide dont le rapport des motifs glycolide aux motifs lactide va de 0 à 3 et qui est soluble dans le benzène et a une viscosité intrinsèque (1 g/100 ml en solution dans le benzène) de moins de 0,5 dl/g ou qui est insoluble dans le benzène et qui a une viscosité intrinsèque (1 g/100 ml en solution dans le chloroforme ou le dioxanne) de moins de 4 dl/g, cette
45 formulation solide ayant été réduite en fines particules, en association avec 50 à 99% en poids d'un support liquide qui convient pour l'injection à des mammifères.

21. Polymère contenant des motifs d'acide lactique et le cas échéant des motifs d'acide glycolique, comprenant 25 à 100 moles % de motifs d'acide lactique et 0 à 75 moles % de motifs d'acide glycolique, et ayant une viscosité intrinsèque (1 g/100 ml en solution dans le chloroforme ou le dioxanne) égale ou supérieure à 0,09 et une viscosité intrinsèque égale ou inférieure à 0,33.

50 22. Procédé de production d'un polymère ou copolymère suivant la revendication 21, qui comprend la polymérisation par décyclisation du dimère cyclique de l'acide lactique, éventuellement en présence du dimère cyclique de l'acide glycolique, à une température élevée en présence d'un catalyseur de polymérisation choisi entre l'oxyde de zinc, le carbonate de zinc, le carbonate de zinc basique, le diéthylzinc, des composés organiques d'étain, le tributylaluminium, des composés de titane de
55 magnésium ou de baryum ou la litharge, et en présence d'un agent de terminaison de chaîne.

60

65

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)